TD Cowen analyst Joseph Thome initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating.
TD Cowen Initiates Coverage On Prime Medicine With Buy Rating
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.